Sooma Oy

Sooma Oy is a medical device company that develops non-invasive brain stimulation technology for treating major neurological and psychiatric disorders. The company initial product uses transcranial Direct Current Stimulation (tDCS) to target major depressive disorder, and is CE Marked for clinical use in Europe. The device delivers low-intensity electrical currents through the scalp to modulate neural activity in specific brain regions, offering a drug-free treatment option for patients who have not responded to traditional antidepressant medications. Sooma technology is designed for use in both clinical and home settings, making neuromodulation therapy accessible outside specialized medical facilities. The company is expanding its therapeutic applications beyond depression to address other neurological and psychiatric conditions. Founded in 2013 and headquartered in Helsinki, Finland, Sooma has raised approximately $6.6 million through Series B funding from investors including Voima Ventures, VERGE, EIC Fund, Innovestor, and Lifeline Ventures.